Drug intelligence / Profile preview

Fuzheng 1

Development stage: Unknown
Lead developer: Guang'anmen Hospital
Administration: Oral

Overview

Fuzheng 1, also referred to as Immunity 1, is a traditional Chinese medicine (TCM) herbal formula developed by Guang'anmen Hospital of the China Academy of Chinese Medical Sciences. It is specifically investigated for its potential to facilitate immune reconstitution in asymptomatic HIV-infected patients who have CD4+ T lymphocyte counts between 350 and 550 cells/μl. The formula is intended to stabilize or increase CD4+ cell counts and potentially delay the initiation of Highly Active Antiretroviral Therapy (HAART).

Other names: Fuzheng No. 1

Beyond the preview

Go deeper on Fuzheng 1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fuzheng 1.

Explore the full profile